• I: Introduction Part I: Diagnosis 1: Improving on Sputum Smear Microscopy for Diagnosis of Tuberculosis in Resource-poor Settings 2: Molecular Diagnosis of Active Pulmonary Tuberculosis 3: Improving on the LJ slope – Automated Liquid Culture 4: Interferon-gamma Release Assays in the Diagnosis of Latent Tuberculosis Infection 5: Measuring Tuberculosis Immune Responses in the Lung – The Correct Target? 6: Sniffing Out Tuberculosis Part II: Measuring Resistance 7: Role of Phenotypic Methods for Drug Susceptibility Testing of M. tuberculosis Isolates in the Era of MDR and XDR Epidemics 8: Genotypic Measures of Antibiotic Susceptibility 9: Molecular Tools for Fast Identification of Resistance and Characterization of MDR/XDR-TB Part III: Understanding Treatment 10: Monitoring Therapy by Bacterial Load 11: Modelling Responses to Tuberculosis Treatment 12: Measuring Gene Expression by Quantitative PCR (qPCR) 13: Transcriptomic Approaches to Mapping Responses to Drug Therapy for Tuberculosis 14: Mycobacterial Lipid Bodies and Resuscitation-promoting Factor Dependency as Potential Biomarkers of Response to Chemotherapy Part IV: Treatment Strategies 15: Clinical Trials in Tuberculosis Chemotherapy: The Challenges 16: The Identification of 2-Aminothiazole-4-carboxylates (ATCs) as a New Class of Tuberculosis Agent: A Lesson in ‘HIT’ Identification 17: Rifamycins Revisited 18: Therapy of the XDR-TB Patient with Thioridazine – An Old Drug with New Applications 19: Vaccines for Tuberculosis

Select Guide Rating